Investor Relations

Corporate Profile

Autolus is a clinical-stage, biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer. Utilising its advanced cell programming and manufacturing technologies, Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours.

Press Releases

Mar 14, 2023
Autolus Therapeutics announces resignation of Chief Financial Officer
- Dr. Lucinda Crabtree to step down with effect from Q3 2023 – - Search for new CFO has been initiated - LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today
Mar 13, 2023
Autolus Therapeutics Has No Business Relationship with Silicon Valley Bank
LONDON, March 13, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today and following recent events with Silicon Valley Bank, announced that the company has no business relationships

Events

More events are coming soon.